Search results for "modality."

showing 10 items of 631 documents

Combined treatment of hidradenitis suppurativa with intense pulsed light (IPL) and radiofrequency (RF)

2019

BACKGROUND Hidradenitis suppurativa is a chronic inflammatory disease with high burden. Treatment options are often unsatisfactory. We assessed the effect of a combination therapy of intense pulsed light (IPL) and radiofrequency (RF). METHODS The explorative study included 47 patients and was performed as a prospective, monocentric, randomized, three-arm parallel-group design trial with a prior 12 weeks observation period. Treatment arms were IPL and RF monotherapies or IPL + RF combination therapy. After 12 weeks, all patients received IPL + RF for additional 12 weeks (cross-over). Primary endpoint was the change in active lesion numbers, secondary endpoint the change in Dermatology Qualit…

AdultMalemedicine.medical_specialtyCombination therapymedicine.medical_treatmentDermatologyIntense pulsed lightChronic inflammatory diseaseLesionYoung Adult030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineCombined treatmentmedicineClinical endpointHumansHidradenitis suppurativaProspective Studies030203 arthritis & rheumatologybusiness.industryIntense Pulsed Light TherapyTreatment optionsMiddle AgedRadiofrequency Therapymedicine.diseaseCombined Modality TherapyDermatologyHidradenitis SuppurativaTreatment OutcomeQuality of LifeFemalesense organsmedicine.symptombusinessJournal of Dermatological Treatment
researchProduct

Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autogra…

2011

Contains fulltext : 95663.pdf (Publisher’s version ) (Closed access) We present results of a phase 3 randomized trial of autografting in chronic lymphocytic leukemia versus observation for responding patients after first- or second-line treatment. The primary objective was to demonstrate that autografting improves the 5-year event-free survival (EFS) from 30% to 50%. There were 223 enrolled patients, 72% men and 28% women, 83% after first and 17% after second-line treatment. Binet stages were progressive A 13%, B 67%, C 20%; at randomization, 59% were in complete remission, and 41% in less than complete remission. Patients were randomized between autografting (n = 112) and observation (n = …

AdultMalemedicine.medical_specialtyCyclophosphamidemedicine.medical_treatmentChronic lymphocytic leukemiaImmunologyHematopoietic stem cell transplantationTransplantation AutologousBiochemistryGastroenterologyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansSurvival rateAgedbusiness.industryHazard ratioHematopoietic Stem Cell TransplantationTranslational research Immune Regulation [ONCOL 3]Cell BiologyHematologyMiddle Agedmedicine.diseaseCombined Modality TherapyLeukemia Lymphocytic Chronic B-CellSurgeryFludarabineEuropeSurvival RateTransplantationTreatment OutcomeAlemtuzumabFemalebusinessmedicine.drug
researchProduct

NOA-05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri.

2011

The NOA-05 multicenter trial was performed to analyze the efficacy of primary chemotherapy with procarbazine and lomustine (PC) in patients with gliomatosis cerebri (GC) and to define clinical, imaging, and molecular factors influencing outcome.Thirty-five patients with previously untreated GC were treated with up to six 56-day courses of 110mg/m(2) lomustine on day 1 and 60mg/m(2) procarbazine on days 8 to 21. The primary endpoint was the rate of patients without therapy failure (defined as progressive disease, death from any cause, or termination of PC therapy before the end of course 4) at 8 months after the beginning of PC chemotherapy.The failure-free survival rate at 8 months was 50.3…

AdultMalemedicine.medical_specialtyEndpoint DeterminationGliomatosis cerebriAntineoplastic AgentsGene mutationProcarbazineGastroenterologyDisease-Free SurvivalLomustineInternal medicineMulticenter trialAntineoplastic Combined Chemotherapy ProtocolsBiomarkers TumorMedicineHumansProspective StudiesKarnofsky Performance StatusSurvival rateDNA Modification MethylasesAgedbusiness.industryTumor Suppressor ProteinsHazard ratioBrainLomustineMiddle Agedmedicine.diseasePrognosisCombined Modality TherapyMagnetic Resonance ImagingNeoplasms NeuroepithelialSurvival AnalysisSurgeryDNA Repair EnzymesTreatment OutcomeNeurologyProcarbazineSample SizeDisease ProgressionFemaleNeurology (clinical)businessProgressive diseasemedicine.drugAnnals of neurology
researchProduct

Urinary glycosaminoglycans in Graves' ophthalmopathy.

1990

An increased accumulation of glycosaminoglycans (GAG) in retrobulbar tissues has been reported in patients with thyroid eye disease. We examined the quantitative urinary GAG excretion in 101 patients with Graves' ophthalmopathy of different classes, 36 patients with Graves' hyperthyroidism without ophthalmopathy, 14 patients with toxic nodular goitre and 103 control subjects. Glycosaminoglycans were isolated from 24-h urine collections by precipitation with cetylpyridinium chloride and ethanol followed by photometrical quantification of hexuronic acids after reaction with carbazole. In comparison with the control group (15.8, 10.4, 21.6 mg/24 h; median, 25th, 75th percentile) a significant …

AdultMalemedicine.medical_specialtyGoiterAdolescentEndocrinology Diabetes and MetabolismGraves' diseaseUrinary systemUrineGraves' ophthalmopathyExcretionEndocrinologyInternal medicineImmunopathologymedicineHumansAgedGlycosaminoglycansAged 80 and overbusiness.industryThyroidMiddle Agedmedicine.diseaseCombined Modality TherapyGraves DiseaseEndocrinologymedicine.anatomical_structurePrednisoneFemalebusinessGoiter NodularClinical endocrinology
researchProduct

Enhancing the efficacy of treatment for temporomandibular patients with muscular diagnosis through cognitive-behavioral intervention, including hypno…

2011

Objective This study evaluated the efficacy of a cognitive-behavioral therapy (CBT), including hypnosis, in patients with temporomandibular disorders (TMDs) with muscular diagnosis. Study Design Seventy-two patients (65 women and 7 men with an average age of 39 years) were selected according to the Research Diagnostic Criteria for TMD, and assigned to the experimental group (n = 41), receiving the 6-session CBT program, and the control group (n = 31). All patients received conservative standard treatment for TMD. The assessment included pain variables and psychologic distress. Results There were significant differences between the groups, the experimental group showing a higher improvement …

AdultMalemedicine.medical_specialtyHypnosismedicine.medical_treatmentResearch Diagnostic CriteriaRelaxation TherapyPathology and Forensic Medicinelaw.inventionYoung AdultRandomized controlled trialFacial PainlawHumansMedicineRadiology Nuclear Medicine and imagingDentistry (miscellaneous)Physical Therapy ModalitiesAgedChi-Square DistributionCognitive Behavioral Therapybusiness.industryStandard treatmentChronic painMiddle AgedTemporomandibular Joint Dysfunction Syndromemedicine.diseaseCombined Modality TherapyCognitive behavioral therapyTreatment OutcomeMultivariate AnalysisPhysical therapyCognitive therapyFemaleSurgeryChronic PainOral SurgerybusinessChi-squared distributionHypnosisOral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
researchProduct

Urrets-Zavalia Syndrome After Combined Trabeculotomy-Trabeculectomy Surgery

2018

We report a case of a rare complication after trabeculotomy combined with a small trabeculectomy with mitomycin C in a young patient with juvenile glaucoma. The patient underwent uneventful surgery. However, postoperatively, he experienced a long-lasting hypotony with the need of 2 revision surgeries and 2 short episodes of high-intraocular pressure. He developed a fixed dilated pupil over time.

AdultMalemedicine.medical_specialtyJuvenile glaucomaMitomycinmedicine.medical_treatmentGlaucomaTrabeculectomy03 medical and health sciencesPostoperative Complications0302 clinical medicinePupil DisordersmedicineHumansTrabeculectomyIntraocular Pressurebusiness.industryMitomycin CHydrophthalmosGlaucomaSyndromeUrrets Zavalia syndromemedicine.diseaseCombined Modality TherapyTrabeculotomySurgeryOphthalmology030221 ophthalmology & optometryComplicationbusiness030217 neurology & neurosurgeryJournal of Glaucoma
researchProduct

Adhesive Small Bowel Obstruction: Predictive Factors of Lack of Response in Conservative Management with Gastrografin

2015

<b><i>Background:</i></b> Gastrografin represents a useful tool in the diagnosis and management of adhesive small bowel obstruction (ASBO). The aim of this study is to identify variables with negative influence in nonoperative management with gastrografin. <b><i>Methods:</i></b> From August 2008 to March 2013, 223 consecutive patients with 235 episodes of ASBO were included and received gastrografin. A protocol for prospective data collection was developed. In order to explore factors related to the failure of nonoperative treatment, univariate and multivariate analysis were performed. <b><i>Results:</i></b> One hundred…

AdultMalemedicine.medical_specialtyMultivariate analysisConservative managementClinical Decision-MakingGastrografinContrast MediaProspective dataTissue Adhesions030230 surgery03 medical and health sciencesPostoperative Complications0302 clinical medicineIntestine SmallmedicineHumansProspective StudiesAdhesive small bowel obstructionProspective cohort studyAgedDiatrizoate MeglumineAged 80 and overbusiness.industryGastroenterologyMiddle Agedmedicine.diseaseCombined Modality TherapySurgeryRadiographyBowel obstructionClinical trialTreatment Outcome030220 oncology & carcinogenesisCohortFemaleSurgerybusinessAdhesive syndromeIntestinal ObstructionPredictive factorsAbdominal surgery
researchProduct

Cigarette Smoking Status at Diagnosis and Recurrence in Intermediate-risk Nonemuscle-invasive Bladder Carcinoma

2013

Objective To study the effect of smoking status at diagnosis on recurrence in intermediate-risk non–muscle-invasive bladder carcinoma treated by transurethral resection (TUR) of the bladder and early intravesical chemotherapy. Methods Tumor characteristics and smoking status were recorded in 395 patients entered in a randomized multicenter trial comparing 2 different schedules of early intravesical chemotherapy. All patients received intravesical epirubicin (80 mg/50 mL) within 6 hours after TUR, followed by 5 more weekly instillations with (arm B) or without (arm A) monthly instillations for 1 year. Smoking habit was investigated at diagnosis through a structured questionnaire. Multivariat…

AdultMalemedicine.medical_specialtyMultivariate analysisTime Factorsintravesical chemotherapy non-muscle invasive bladder cancerUrologymedicine.medical_treatmentcigarette smokingKaplan-Meier EstimateCystectomyGastroenterologyDisease-Free SurvivalSettore MED/24 - UrologiaCystectomyCigarette smokingRisk FactorsMulticenter trialInternal medicinemedicineCarcinomaHumansAgedEpirubicinProportional Hazards ModelsAged 80 and overAntibiotics AntineoplasticProportional hazards modelbusiness.industryCarcinomaSmokingMiddle AgedFormer Smokermedicine.diseaseintermediate-risk tumorrecurrence.Combined Modality TherapySurgeryUrinary Bladder NeoplasmsMultivariate AnalysisFemaleNeoplasm Recurrence LocalbusinessEpirubicinmedicine.drug
researchProduct

Mature Survival Data for 176 Patients Younger Than 60 Years With Primary Myelofibrosis Diagnosed Between 1976 and 2005: Evidence for Survival Gains i…

2009

In the past 20 years, management of primary myelofibrosis (PMF) has incorporated new treatment approaches, but survival benefits have not been confirmed in controlled studies. This retrospective study includes 176 consecutive patients younger than age 60 years in whom PMF was diagnosed during a 30-year period (1976-2005). Median age at diagnosis was 50 years (range, 18-59 years), and 98 patients (55%) were men. At the time of this report, 99 patients (56%) had died; the 77 surviving patients were followed up for a median of 8 years (range, 4-24 years). Overall median survival was 9.2 years, and 15- and 20-year survival rates were 32% and 20%, respectively. According to the Dupriez Prognosti…

AdultMalemedicine.medical_specialtyMultivariate analysisTransplantation ConditioningAdolescentmedicine.medical_treatmentDiseaseHematopoietic stem cell transplantationKaplan-Meier EstimateDisease-Free SurvivalSettore MED/15 - Malattie Del Sanguemyelofibrosis survivalSurvival dataInternal medicinemedicineHumansMyelofibrosisSurvival rateProportional Hazards ModelsRetrospective Studiesbusiness.industryProportional hazards modelBrief ReportHematopoietic Stem Cell TransplantationRetrospective cohort studyGeneral MedicineMiddle Agedmedicine.diseaseCombined Modality TherapyUnited StatesSurgerySurvival RatePrimary MyelofibrosisMultivariate AnalysisFemalebusiness
researchProduct

High-Risk Patients with Differentiated Thyroid Cancer T4 Primary Tumors Achieve Remnant Ablation Equally Well Using rhTSH or Thyroid Hormone Withdraw…

2013

Few data exist on using thyrotropin alfa (recombinant human thyroid-stimulating hormone [rhTSH]) with radioiodine for thyroid remnant ablation of patients who have T4 primary tumors (invasion beyond the thyroid capsule).A retrospective chart review protocol at nine centers in Europe was set up with special waiver of need for informed consent, along with a careful procedure to avoid selection bias when enrolling patients into the database. Data on 144 eligible patients with T4 tumors were collected (T4, N0-1, M0-1; mean age 49.7 years; 65% female; 88% papillary cancer). All had received (131)I remnant ablation following TSH stimulation with rhTSH or thyroid hormone withdrawal (THW) since Jan…

AdultMalemedicine.medical_specialtyNeoplasm ResidualEndocrinology Diabetes and Metabolismmedicine.medical_treatmentUrologyRemnant ablationIodine RadioisotopesYoung AdultEndocrinologyClinical endpointmedicineHumansThyroid NeoplasmsThyrotropin AlfaThyroid cancerAgedRetrospective StudiesAged 80 and overHigh risk patientsbusiness.industryThyroidCancerMiddle Agedmedicine.diseaseAblationCombined Modality TherapySurgeryTreatment Outcomemedicine.anatomical_structureThyroidectomyFemalebusinessHormoneThyroid
researchProduct